Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

INTRODUCTION: Several studies have demonstrated that non-small cell lung cancer patients (NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations have poor clinical outcomes in response to treatment with programmed death-1 (PD-1) inhibitors. However, it remains unclear whether EGFR-mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Ken, Horinouchi, Hidehito, Tanaka, Midori, Higashiyama, Ryoko, Shinno, Yuki, Sato, Jun, Matsumoto, Yuji, Okuma, Yusuke, Yoshida, Tatsuya, Goto, Yasushi, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810613/
https://www.ncbi.nlm.nih.gov/pubmed/32705363
http://dx.doi.org/10.1007/s00432-020-03329-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810613/
https://www.ncbi.nlm.nih.gov/pubmed/32705363
http://dx.doi.org/10.1007/s00432-020-03329-0

Ejemplares similares